Examining Cost-Effectiveness of Initial Diagnostic Exams for Microscopic Hematuria   

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, APRIL 17, 2017

Media Advisory: To contact corresponding author Joshua A. Halpern, M.D., M.S., email Jennifer Gundersen at jeg2034@med.cornell.edu.

Related material: The commentary, “Asymptomatic Microscopic Hematuria – Rethinking the Diagnostic Algorithm,” by Leslee L. Subak, M.D., and Deborah Grady, M.D., M.P.H., of the University of California, San Francisco, also is available on the For The Media website.

Related audio material: An interview with the authors is available for preview on the For The Media website. The podcast will be live when the embargo lifts on the JAMA Internal Medicine website.

To place an electronic embedded link in your story: Links will be live at the embargo time: http://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2017.0739

 

JAMA Internal Medicine

Detecting red blood cells in the urine of asymptomatic patients who don’t see blood when they urinate (asymptomatic microscopic hematuria) is common but it can signal cancer in the genitourinary system.

Routine urinalysis for screening of genitourinary cancer isn’t recommended by any major health group but patients who undergo urinalysis for a variety of other reasons are often found to have microscopic hematuria, which prompts further evaluation. A new article published by JAMA Internal Medicine explores the cost-effectiveness of four initial diagnostic protocols for these patients.

Joshua A. Halpern, M.D., M.S., of Weill Cornell Medicine, New York, and his coauthors analyzed the cost-effectiveness of: computed tomography (CT) alone, cystoscopy (using a scope to examine the urinary tract) alone, CT and cystoscopy combined, and renal (kidney) ultrasound and cystoscopy combined.

The combination of cystoscopy and renal ultrasound was the most cost-effective with an incremental cost of $53,810 per cancer detected, according to the results.

“The use of ultrasound in lieu of CT as the first-line diagnostic strategy will reduce the cost, morbidity and national expenditures associated with evaluation of AMH [asymptomatic microscopic hematuria]. Clinicians and policy makers should consider changing future guidelines in accordance with this finding,” the article concludes.

To read the full study, please visit the For The Media website.

(JAMA Intern Med. Published online April 17, 2017. doi:10.1001/jamainternmed.2017.0739; available pre-embargo at the For The Media website.)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

#  #  #

 

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email mediarelations@jamanetwork.org.